Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
34,100
Employees34,100
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
34,100
Employees34,100

BMY Key Statistics

Market cap
111.80B
Market cap111.80B
Price-Earnings ratio
18.40
Price-Earnings ratio18.40
Dividend yield
4.55%
Dividend yield4.55%
Average volume
12.81M
Average volume12.81M
High today
$55.52
High today$55.52
Low today
$54.36
Low today$54.36
Open price
$54.61
Open price$54.61
Volume
12.28M
Volume12.28M
52 Week high
$63.33
52 Week high$63.33
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

As of today, Bristol-Myers Squibb(BMY) shares are valued at $54.57. The company's market cap stands at 111.8B, with a P/E ratio of 18.40 and a dividend yield of 4.6%.

As of 2026-01-22, Bristol-Myers Squibb(BMY) stock has fluctuated between $54.36 and $55.52. The current price stands at $54.57, placing the stock +0.4% above today's low and -1.7% off the high.

The Bristol-Myers Squibb(BMY)'s current trading volume is 12.28M, compared to an average daily volume of 12.81M.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.

In the last year, Bristol-Myers Squibb(BMY) shares hit a 52-week high of $63.33 and a 52-week low of $42.52.

BMY News

TipRanks 16h
Janux Therapeutics enters exclusive license agreement with Bristol Myers

Janux Therapeutics (JANX) announced a collaboration and exclusive worldwide license agreement with Bristol Myers (BMY). Under the terms of the agreement, the co...

Simply Wall St 23h
Assessing Bristol Myers Squibb Valuation After New Microsoft Lung Cancer Detection Partnership

Advertisement Why Bristol-Myers Squibb (BMY) is back on investors’ radar Bristol-Myers Squibb (BMY) just announced a partnership with Microsoft that uses FDA...

Assessing Bristol Myers Squibb Valuation After New Microsoft Lung Cancer Detection Partnership
TipRanks 1d
Bristol-Myers Squibb’s KarXT Safety Study: What Long-Term Urological Data Could Mean for BMY Investors

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Study Overview: Bristol-Myers Squibb is...

Analyst ratings

60%

of 30 ratings
Buy
36.7%
Hold
60%
Sell
3.3%

More BMY News

TipRanks 3d
Bristol-Myers Squibb Stock Slips Despite an AI Collaboration with Microsoft

Bristol-Myers Squibb (BMY) stock slipped on Tuesday despite news of an artificial intelligence (AI) agreement with tech giant Microsoft (MSFT). This deal will h...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.